Enliven Therapeutics (NASDAQ:ELVN) CFO Sells $231,572.64 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer directly owned 38,000 shares in the company, valued at $1,462,240. This trade represents a 13.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, September 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $50.35, for a total transaction of $303,006.30.
• On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44.

Enliven Therapeutics Trading Down 1.0%

NASDAQ ELVN opened at $41.52 on Friday. The firm’s 50 day moving average price is $50.26 and its 200-day moving average price is $47.98. Enliven Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, research analysts expect that Enliven Therapeutics, Inc. will post -1.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. KBC Group NV acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at about $38,000. Sterling Capital Management LLC boosted its holdings in Enliven Therapeutics by 1,180.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock worth $88,000 after buying an additional 1,771 shares during the last quarter. State of Wyoming acquired a new stake in Enliven Therapeutics in the 2nd quarter worth about $96,000. FNY Investment Advisers LLC purchased a new stake in Enliven Therapeutics during the 2nd quarter worth approximately $126,000. Finally, Royal Bank of Canada increased its stake in Enliven Therapeutics by 345.0% during the 1st quarter. Royal Bank of Canada now owns 5,424 shares of the company’s stock worth $212,000 after buying an additional 4,205 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ELVN shares. Barclays began coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price target on the stock. JonesTrading boosted their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Stifel Nicolaus upped their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Ten analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.44.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.